Regular monitoring of patients with CLL is essential. This will be monthly at the start, every 3-12 months in the first year, and yearly thereafter
The purpose of follow-up is to identify signs of relapse or complications.
It is important to tell patients to report new symptoms or side effects as soon as possible.
